IPHA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than merely 6.08% of US-listed equities with positive expected earnings growth.
Innate Pharma SA's stock had its IPO on October 18, 2019, making it an older stock than just 0.76% of US equities in our set.
With a year-over-year growth in debt of 309.54%, Innate Pharma SA's debt growth rate surpasses 94.83% of about US stocks.
Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are DRRX, VCNX, VNE, CLDX, and PULM.
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.
Companies Reporting Before The Bell • China Online Education Group (NYSE: COE ) is projected to report quarterly earnings at $0.11 per share on revenue of $67.54 million. • General Finance (NASDAQ: GFN ) is estimated to report quarterly earnings at $0.03 per share on revenue of $78.75 million. • NAPCO Security (NASDAQ: NSSC ) is expected to report quarterly earnings at $0.18 per share on revenue of $26.46 million. • Innate Pharma (NASDAQ: IPHA ) is expected to report earnings for its second quarter. • Uxin (NASDAQ: UXIN ) is expected to report quarterly loss at $0.09 per share on revenue of … Full story available on Benzinga.com
Innate Pharma (IPHA) has obtained funding of €6.8M under the PSPC-COVID call for projects to support its COVID-19 research and development activities. PSPC-COVID is a program established by the French government to support the development of therapeutic solutions with a preventative or curative aim for COVID-19. As part of this...
The FDA has lifted partial clinical hold placed on Innate Pharma SA's (IPHA) TELLOMAK Phase II clinical trial, evaluating the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas. The company is taking operational measures to re-activate trial in U.S. The agency's decision is based on a quality assessment...